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We sought to characterise whether dexamethasone (DEX) may enhance tumour response to docetaxel in in vitro and in vivo models
of metastatic prostate cancer (CaP). In vitro experiments conducted on PC3 and human bone marrow endothelial cells (hBMECs)
determined that administration of DEX (10nM) reduced constitutive nuclear factor-kB (NF-kB) activity, decreasing interleukin (IL)-8,
CXCL1 and VEGF gene expression in PC3 cells. Dexamethasone also attenuated docetaxel-induced NF-kB and activator protein-1
transcription and reduced docetaxel-promoted expression/secretion of IL-8 and CXCL1 in PC3 and hBMECs. Although DEX failed
to enhance docetaxel cytotoxicity on PC3 cells, DEX potentiated the antiangiogenic activity of docetaxel in vitro, further reducing
vessel area and vessel length in developing endothelial tubes (Po0.05). Docetaxel had a potent antiangiogenic activity in the dorsal
skin flap-implanted PC3 tumours in vivo. Small blood vessel formation was further suppressed in tumours co-treated with docetaxel
and DEX, substantiated by an increased average vessel diameter and segment length and a decreased number of branch points in the
residual tumour vasculature (Po0.001). Our data show that DEX potentiates the antiangiogenic activity of docetaxel, suggesting a
putative mechanism for the palliative and survival benefits of these agents in metastatic CaP.
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Prostate cancer (CaP) is now the second most common cause of
male cancer death in the Western society. Castration therapy
(either surgical orchidectomy or luteinizing hormone releasing
hormone agonists) is initially effective in treating recurrent or
metastatic CaP. However, the majority of these patients will
become refractory to castration as the cancer loses dependence on
androgen-signalling. As a further complication, castration-resis-
tant CaP (CRPC) is poorly sensitive to conventional cytotoxic
chemotherapy. However, two recent phase III trials, the TAX 327
and SWOG 9916 trials, have reported a survival benefit together
with superior pain response, PSA response rate and improvement
in quality of life in patients with hormone refractory, metastatic
CaP receiving docetaxel (Taxotere
-) as opposed to mitoxantrone
therapy. Accordingly, docetaxel has become the chemotherapy of
choice for men with metastatic CRPC (Petrylak et al, 2004;
Tannock et al, 2004).
Glucocorticoids, such as dexamethasone (DEX), have also been
shown to exhibit single-agent activity in CRPC. Low dose, daily DEX
administration has been reported to yield biochemical PSA response
rates of up to 49% in CRPC (Venkitaraman et al,2 0 0 8 ) .T h e
mechanism by which glucocorticoids exert their effect in cancer is not
well elucidated, although several mechanisms have been postulated.
Glucocorticoids have been shown to interfere with the transcriptional
activity of nuclear factor-kB( N F - kB) and activator protein-1 (AP-1)
(Nishimura et al, 2001), resulting in the suppression of the
interleukin-6 (IL-6) and the NF-kB–IL-6 pathways in CaP (Akakura
et al, 2003; De Bosscher et al, 2003). Dexamethasone has also been
shown to inhibit angiogenesis in a CaP xenograft model, reducing cell
and tumour IL-8 and VEGF expression in in vitro and in vivo assays,
respectively (Yano et al,2 0 0 6 ) .
CXC-chemokines including IL-8 have an established role in
promoting the progression of CaP (Waugh et al, 2008).
Interleukin-8 expression has been shown to be elevated in CaP
tissue by immunohistochemistry (Huang et al, 2005; Murphy et al,
2005) and by in situ hybridisation (Uehara et al, 2005), whereas
overexpression of IL-8 has been detected in the serum of CaP
patients (Veltri et al, 1999; McCarron et al, 2002). Furthermore,
IL-8 expression in CaP tissue has been associated with increased
biochemical recurrence (Caruso et al, 2008). Consistent with this,
studies in athymic mice have correlated the increased expression
of IL-8 in implanted human CaP cells with increased vascularisa-
tion of the tumours and an enhanced tumourigenic and metastatic
potential (Inoue et al, 2000; Kim et al, 2001). Other studies have
determined the relevance of IL-8 signalling to the development of
androgen-independence (Araki et al, 2007; Seaton et al, 2008), CaP
cell proliferation (Murphy et al, 2005) and CaP cell survival in
response to environmental and chemotherapy/biological agents
(Maxwell et al, 2007; Wilson et al, 2008a,b).
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fluid retention and hypersensitivity responses to taxane adminis-
tration and were present as an element of the TAX327 and
SWOG9916 trial regimens. Furthermore, given that DEX exhibits
single-agent activity in this disease (Venkitaraman et al, 2008), we
established this pre-clinical study to determine whether two agents
used clinically and often together during therapy may act to
enhance the activity of the other in experimental models of CRPC.
Therefore, our experiments focused on elucidating the effect of
DEX and docetaxel in modulating CXC-chemokine expression and
signalling within CRPC cells, with the intent of characterising a
mechanism to explain how DEX might enhance docetaxel response
in this disease.
MATERIALS AND METHODS
Chemical and reagents
Chemicals were purchased from Sigma Chemical Co. (St Louis,
MO, USA) unless otherwise stated.
Cell culture
Human PC3 and LNCaP cells were sourced and grown in RPMI
1640 medium supplemented with 10% fetal bovine serum and
4m ML -glutamine (Invitrogen Ltd, Paisley, UK) as previously
described (Maxwell et al, 2007; Wilson et al, 2008a). The hBMEC
line was kindly provided by Dr Babette B Weksler of Weill Medical
College, Cornell University, New York. Human BMECs were
maintained in DMEM medium supplemented with 5% FCS, 3%
L-glutamine and HEPES (10mM). All cultures were maintained in a
humidified chamber at 371C with 5% CO2.
Cell count analysis
Cells were seeded into 24-well plates (1 10
5 cells per well) in
RPMI 1640 medium and allowed to attach overnight. Cells were
then treated with DEX (10nM). Plates were incubated in a
humidified chamber at 371C with 5% CO2 for 24, 48 or 72h, and
the cells were trypsinised and counted in triplicate using a Coulter
Z series particle count and size analyzer (Beckman Coulter, High
Wycombe, UK). Cell numbers were normalised to control values.
Quantitative real-time PCR (QPCR)
Total RNA was isolated using RNAStat60 (Biogenesis, Oxford, UK)
according to the manufacturer’s instructions. For real-time PCR,
10mg of total RNA was oligo(dT) reverse transcribed using MMLV-
RT (Invitrogen) according to the manufacturer’s instructions. The
cDNA (100ng) was mixed with primers (2mM), sterile water and
SYBR Green PCR mastermix (Finnzymes, Espoo, Finland). The
primer sequences were as follows: 18S: forward, 50-CAT TCg TAT
TGC GCC gCT-30;r e v e r s e ,5 0- CGA Cgg TAT CTg ATC gTC-30;I L - 8 :
forward, 50-ATg ACT TCC AAg CTg gCC gTg g; reverse, 50- CAT
AAT TTC TGT GTT ggC gCA gTg Tgg; CXCL1: forward, CCC AAg
AAC ATC CAA AgT gTC A; reverse, gTg gCT ATg ACT TCg gTT
Tg; VEGF: forward, 50- AgC TAC TgC CAT CCA ATC gA; reverse,
50- ggT gAg gTT TgA TCC gCA TA. Real-time PCR was carried out
in a 96-well plate using an Opticon 2 Continuous Fluorescence
Detector (Biorad, Hertfordshire, UK). Amplification was 951C for
15min, and 45 cycles at 951C for 15s, 551C for 30s and 721C for
60s. The threshold cycle (Ct), which indicates the relative
abundance of a particular transcript, was calculated for each
reaction by the Opticon 2 system. Expression levels were
determined from standard curve dilutions and normalised for 18s.
Transfection and luciferase assay
Cells were plated in six-well plates (1 10
5 cells per well) in RPMI
1640 medium and incubated for 48h at 371C with 5% CO2. Cells
were transfected using GeneJuice transfection reagent (Merck
Chemicals. Nottingham, UK), according to manufacturer’s proto-
col, with 2mg pGL3 basic vector (Promega, Madison, WI, USA) or
2mg of an NF-kB-LUC plasmid (kindly provided by Dr James
Purcell, QUB) or 0.5mg of an AP-1-LUC plasmid (kindly provided
by Dr Massimo Gadina, QUB). Cells were also co-transfected with
0.2mgo faRenilla luciferase plasmid as a transfection control for
pGL3 and NF-kB or 0.01mgo faRenilla luciferase plasmid as a
transfection control for AP-1. Cells were incubated for 24h before
drug addition. The drug of interest was added for the desired time
and the samples were analysed by luciferase assay using the
Promega Dual Luciferase assay kit (Promega) according to the
manufacturer’s protocol.
Enzyme-linked immunosorbent assay (ELISA)
Cells were plated in 24-well plates (5 10
4 cells per well) in RPMI
1640 medium. Following an overnight incubation, the medium was
replaced with fresh media, docetaxel (1nM)o rD E X( 1 0 n M), or a
combination of both drugs were added to cells for the indicated
time. A time-matched control with no drug was also included. The
supernatant was removed from the cells and centrifuged at 1000g
for 5min to remove any cell debris and the supernatant was stored
at  201C until assayed. The cell number in each well was determined
by parallel cell count analysis. CXCL8 levels were measured using
the Pelikine Compactt IL-8 ELISA Kit (Sanquin Reagents,
Amsterdam, The Netherlands), whereas CXCL1 levels were deter-
mined using the Quantikine
s kit (R&D Systems, Abingdon, UK).
The manufacturer’s instructions were used in the application of each
ELISA kit. Absorbance readings were taken at 450nm using a
microwell plate reader (Molecular Devices, Wokingham, UK).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
Cells were seeded into 96-well plates (3 10
3 cells per well) in
RPMI 1640 medium and allowed to attach overnight. Serial
dilutions of docetaxel (kind gift from Belfast City Hospital
Pharmacy) or DEX were added to the cells alone and, in the case
of docetaxel, in combination with a fixed concentration of DEX
(10nM). In other experiments, cells were treated with 5mM BAY-11-
7082 (Calbiochem, La Jolla, CA, USA), a monoclonal neutralising
antibody for IL-8, at a final concentration of 4mgml
 1 (R&D
Systems, Abingdon, UK) or a selective CXCR2 receptor antagonist
AZ10397767 (Walters et al, 2008) (kindly provided by Dr Simon T.
Barry, AstraZeneca, Alderley Park, UK). Plates were incubated in a
humidified chamber at 371C with 5% CO2 for 72h, then 50ml MTT
(2mgml
 1) was added and the plates returned to the incubator for
4h. Medium and any unmetabolised MTT was aspirated from the
wells and the formazan crystals were dissolved in 100ml dimethyl
sulphoxide. Absorbance was read at 570nm using a microplate
reader (Molecular Devices).
Angiogenesis assay
AngioKit (GB patent 2331763) consisting of one 24-well pre-seeded
tissue culture plate containing early stage co-cultures of human
endothelial cells and other human cells, five 25ml single use
bottles of optimised media, positive (VEGF) and negative
(suramin) controls and CD31 (PECAM-1) staining kit was supplied
by TCS CellWorks Ltd (Buckingham, UK). Fresh media, media
with positive control (VEGF), media with suramin or media plus
docetaxel (1nM), DEX (10nM) or a combination of both was added
to each well on days 1, 4, 7 and 9 as per the manufacturer’s
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sinstructions. Cells were treated with each test compound in
triplicate. Plates were incubated in a humidified chamber at 371C
with 5% CO2 for 11 days, then fixed and stained with anti-CD31
according to the manufacturer’s instructions. Images were
analysed using a LEICA DMLB microscope and LUICA measure-
ment software (Leica Microsystems (UK) Ltd, Milton Keynes, UK).
For each well, 15 fields were analysed using the five-times
objective. The length and area of each vessel were measured using
the LUICA measurement software. Mean vessel length and area, as
well as total vessel length and area in 15 fields in each of the
triplicate wells were calculated (Microsoft Excel software).
Dorsal skin flap model
Imaging of the tumour vasculature in an implanted PC3 tumour
was conducted in 12-week-old male BALB-c SCID mice as
previously described (O’Rourke et al, 2008). Briefly, a viewing
chamber was attached to a raised skin flap on the dorsal flank of
the mouse under anaesthesia and a fragment (0.5mm) of PC3
prostate tumour (excised from a donor mouse) was placed on the
exposed microvascular bed. The PC3 tumour vasculature was
imaged 7 days postsurgery, (tumours measured 2mm in diameter),
by injection of 50ml of 150kDa FITC-labeled dextran (50mgml
 1)
into the tail vein under light anaesthesia. The viewing chamber was
illuminated with a mercury lamp, and the FITC signal was detected
with an ORCA-ER camera system (Hamamatsu Photonics, Welwyn
Garden City, UK). Images were recorded using Image J software
(NIH, Bethesda, MD, USA). Mice then received DEX (10nM),
docetaxel (0.5nM) or a combination of DEX (10nM)/docetaxel
(0.5nM), administered directly to the sealed chamber on days 8, 11
and 14 post-implantation. Control animals received injections of
PBS at similar time points. Imaging was repeated at days 9, 11, 15
and 18 post-implantation. Experiments were carried out in
accordance with the Animal (Scientific Procedures) Act 1986 and
conformed to the current United Kingdom Coordinating Committee
on Cancer Research guidelines.
Statistical analysis
Two-tailed Student’s t-tests were performed using GraphPad Prism
4.0 software to compare mean values in drug-treated CaP and
endothelial cells for each of the following in vitro experiments:
analysis of gene expression and secretion, comparison of cell
viability and determination of vessel formation in the AngioKit
assay. Statistical analysis of the tumour vascular parameters in the
dorsal skin flap model was performed using a one-way ANOVA
(Microsoft Excel software).
RESULTS
Effect of DEX on basal NF-jB activity in PC3 cells
Constitutive activation of the NF-kB transcription factor has been
reported in CaP and is associated with disease progression,
chemoresistance, angiogenesis and metastasis (Huang et al, 2001;
Fradet et al, 2004; Ross et al, 2004; Shukla et al, 2004; Sweeney
et al, 2004; Domingo-Domenech et al, 2005). Nuclear factor-kB has
been reported to induce the transcription of proinflammatory
genes, many of which have been implicated in each of the above
phenotypes. Given the anti-inflammatory activity of glucocorti-
coids, we initially determined the effect of DEX administration
upon the constitutive transcriptional activity of NF-kB in PC3 cells.
The PC3 cells were transfected with the pGL3-NF-kB luciferase
construct. Addition of DEX (10nM) was shown to effect a sustained
repression of NF-kB-luciferase activity in transfected PC3 cells.
The maximal inhibition of NF-kB activity was observed 6h post-
administration of DEX, attenuating NF-kB activity to 39% of that
in control cells (Po0.05) (Figure 1A).
DEX downregulates IL-8 and VEGF expression in PC3 cells
Having shown that DEX downregulates NF-kB activity, we
confirmed whether DEX modulated the expression of the
proangiogenic NF-kB transcriptional target, IL-8. Using QPCR,
we observed a time-dependent decrease in IL-8 transcript levels in
PC3 cells following a single administration of DEX (10nM),
suppressing the constitutive IL-8 mRNA transcript expression in
PC3 cells to 38% of that in untreated cells 48h post-treatment with
DEX (Po0.01) (Figure 1B). Similarly, administration of DEX was
also shown to reduce the expression of the related proangiogenic
CXC-chemokine, CXCL1 (Po0.05 at the 48h time point). In a
further analysis, we determined the effect of DEX on the gene
expression of VEGF, another angiogenesis-promoting factor whose
transcription is also regulated by NF-kB activity. The VEGF mRNA
transcript levels also showed a time-dependent decrease following
administration of DEX (10nM) to PC3 cells that was evident within
6h and was maximal (45%) by 24h (Figure 1B).
To confirm that the observed downregulation of IL-8 mRNA
transcript levels in PC3 cells corresponded with a decreased rate of
IL-8 secretion, we performed an ELISA. The PC3 cells were treated
with a single dose of DEX (10nM), and media samples were
collected between 6 and 72h post-administration of the gluco-
corticoid. To account for any time-dependent accumulation of
secreted IL-8 in cultured PC3 cells, we collected a time-matched
control sample alongside each treated sample. The secretion of
IL-8 was normalised relative to cell number and expressed as a
percentage of the time-matched, untreated sample. Administration
of DEX (10nM) effected a time-dependent suppression of IL-8
secretion from PC3 cells, reaching a maximal inhibition at 24h
(Po0.05). However, the level of IL-8 secretion recovered to
baseline levels 72h post-treatment (Figure 1C). Similarly, experi-
ments with DEX effected a similar reduction in basal IL-8 secretion
from androgen-dependent CaP cells (LNCaP), reducing the
secretion to 75% of basal levels 24h after addition of DEX
(Po0.05) (data not shown). As in the clinical setting, DEX is
administered daily, we also determined the effect of daily DEX
(10nM) on IL-8 and CXCL1 secretion in PC3 cells; this prevented
the return to basal levels of IL-8 secretion and also resulted in a
sustained, although smaller, decrease in CXCL1 secretion
(Figure 1D).
Effect of DEX on PC3 and endothelial cell proliferation
Experiments were established to determine the effect of DEX on
PC3 cell proliferation. The PC3 cells were treated with DEX over a
concentration range of 0.1nM to 10mM for 72h and an MTT assay
performed to assess cell viability. Dexamethasone had no
inhibitory effect on PC3 cell proliferation at any concentration
studied over this 72h period (data not shown). The effect of DEX
on PC3 cell growth over a time course was also examined. Cell
count analysis was performed at 24, 48 and 72h after addition of
10nM DEX to PC3 cells. Relative to unstimulated cells, adminis-
tration of 10nM DEX was observed to have no significant effect on
cell proliferation (data not shown). Dexamethasone (0–1mM) also
had no inhibitory effect on LNCaP or hBMEC cell proliferation
(data not shown).
DEX attenuates docetaxel-induced NF-jB and AP-1 activity
in PC3 cells
Patients with CRPC frequently receive DEX in combination with
docetaxel. Using the aforementioned luciferase reporter assays, we
studied the impact of administering DEX and docetaxel in
combination upon NF-kB and AP-1 transcriptional activity in
PC3 cells. Measurements of transcription factor activity were
conducted 24h post-administration of the drug treatments. The
PC3 cells were treated with a single dose of docetaxel (1nM), alone
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sor co-administered with DEX (10nM). Docetaxel doubled NF-kB
activity in the PC3 cells compared with control unstimulated cells
(Po0.05); however, this was reduced to basal levels in the presence
of DEX (Po0.05 relative to docetaxel alone) (Figure 2A). Similarly,
docetaxel administration increased AP-1 transcriptional activity in
PC3 cells by over two-fold (Po0.01). Co-administration of DEX
attenuated but did not abrogate the docetaxel-induced AP-1
activity in these PC3 cells (Po0.01) (Figure 2B).
Having shown that DEX attenuated docetaxel-induced potentia-
tion of NF-kB and AP-1 transcriptional activity, we confirmed the
effect of administering these drugs alone or in combination upon
the regulation of the IL-8 and CXCL1 genes. The PC3 cells were
treated with docetaxel (1nM) alone, or concurrently with DEX
(10nM). The mRNA samples were harvested from the cells 24h
post-treatment. The mRNA transcript levels for IL-8 and CXCL1
were then quantified relative to that of the housekeeping gene 18S
using the established, gene-specific QPCR assays. Docetaxel
administration resulted in increasing IL-8 mRNA and CXCL1
mRNA transcript levels to over 1.5-fold of that detected in time-
matched, untreated cell populations (Figure 2C); this was
attenuated by the concurrent administration of DEX (Po0.05 in
both cases).
We also used an ELISA to determine the impact of docetaxel on
IL-8 and CXCL1 secretion from PC3 cells. All values for CXC-
chemokine secretion were normalised against cell number and
expressed as a percentage of that measured in time-matched,
untreated samples. In initial experiments, we conducted a time
course to determine how docetaxel influenced the rate and
magnitude of IL-8 secretion from PC3 cells. Docetaxel potentiated
IL-8 secretion in a time-dependent manner, increasing the
extracellular level of this chemokine to 175 and 160% of that
determined in untreated, time-matched controls, 16 and 24h post-
addition of this taxane, respectively (Po0.05) (data not shown). In
further experiments, the level of IL-8 in the cell media was
quantified and normalised 24h post-administration of docetaxel,
in the absence and presence of DEX (10nM). Docetaxel induced
IL-8 secretion to 168% of that detected in untreated PC3 cells
(Po0.001). However, concurrent treatment with DEX attenuated
the docetaxel-induced increase in IL-8 secretion, reducing IL-8
secretion to approximately 10% below that observed in untreated
cells (Po0.001) (Figure 2D). A similar trend was determined for
the effect of these drugs in promoting CXCL1 secretion from PC3
cells. Again, DEX was shown to reverse docetaxel-induced CXCL1
secretion (Po0.05) (Figure 2D).
DEX attenuates docetaxel-induced IL-8 expression and
secretion in endothelial cells
Further experiments were conducted on hBMECs to determine the
effects of DEX, docetaxel and a combination of DEX with docetaxel
on IL-8 and CXCL1 gene transcription and the secretion of
these CXC-chemokines by endothelial rather than tumour cells.
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Figure 1 Dexamethasone (DEX) decreases expression and secretion of proangiogenic CXC-chemokines in PC3 cells. (A) Bar graph illustrating the effect
of 10nM DEX on NF-kB-driven transcriptional activity in PC3 cells transfected with a pGL3-NF-kB-LUC plasmid compared with time-matched controls
transfected with an empty vector and normalised against Renilla luciferase activity as described in Materials and Methods. Data shown are the mean±s.e.m.
of six independent experiments. (B) Bar graph illustrating the relative mRNA transcript levels for the proangiogenic factors IL-8, CXCL1 and VEGF in PC3
cells, determined by QPCR over a 48h time course post-treatment with 10nM DEX. Values shown represent the mean±s.e.m. value, determined from
three or four independent experiments. (C) Bar graph illustrating the relative secretion of the CXC-chemokine IL-8 from PC3 cells following treatment with
a single administration of 10nM DEX. The concentration of IL-8 secreted into the culture media was determined by ELISA. Data shown are the
mean±s.e.m. value of six independent experiments. (D)A si n( C), except that 10nM DEX was administered to the PC3 cells every 24h. Data shown are
the mean±s.e.m. value of four independent experiments. Statistically significant differences in activity, transcript levels or secretion were determined using a
two-tailed Student’s t-test analysis. *Po0.05; **Po0.01.
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tumour cells. As observed before, addition of DEX to these
endothelial cells reduced IL-8 transcript levels to 75% of that
observed in untreated, time-matched control cells. Administration
of docetaxel (1nM) was shown to increase IL-8 mRNA transcript
levels to the levels approaching double that of control levels,
whereas co-treatment with DEX reduced IL-8 transcript levels to
73% of that observed in untreated, time-matched control cells
(Po0.05) (Figure 2E). Similarly, DEX was shown to reverse
docetaxel-induced CXCL1 mRNA transcript levels in these
endothelial cells (Po0.05) (Figure 2E). Furthermore, using ELISAs,
we were able to confirm that co-administration of DEX attenuated
the docetaxel-induced increase in IL-8 and CXCL1 secretion from
hBMECs (Po0.05 in either case) (Figure 2F).
Effect of DEX administration upon docetaxel cytotoxicity
in CRPC and endothelial cells
Nuclear factor-kB and AP-1 transcription are each associated with
promotion of cell survival and cell proliferation. We therefore
examined the cytotoxicity of docetaxel (0.01nM to 100mM) in PC3
cells for 72h, when administered alone or in combination with
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Figure 2 Effect of dexamethasone (DEX) upon docetaxel-induced transcriptional regulation and potentiation of CXC-chemokine expression/secretion
by PC3 and endothelial cells. (A) Bar graph illustrating the effect of 1nM docetaxel (Doc) or 10nM DEX, singly or in combination, upon NF-kB-driven
transcriptional activity in PC3 cells transfected with a pGL3-NF-kB-LUC plasmid measured 24h post-addition of the drugs. This is compared with time-
matched controls transfected with an empty vector and normalised against Renilla luciferase activity as described in Materials and Methods. Data shown are
the mean±s.e.m. of four independent experiments. (B) Bar graph illustrating the effect of 1nM Doc or 10nM DEX, singly or in combination, upon AP-1-
driven transcriptional activity in PC3 cells transfected with a pGL3-AP-1-LUC plasmid measured 24h post-administration of the drugs. This is compared with
time-matched controls transfected with an empty vector and normalised against Renilla luciferase activity as described in Materials and Methods. Data shown
are the mean±s.e.m. of four independent experiments. (C) Bar graph illustrating the relative mRNA transcript levels for the proangiogenic factors IL-8 and
CXCL1 in PC3 cells 24h post-treatment with 1nM Doc or 10nM DEX, administered singly or in combination. Transcript levels were determined using the
established QPCR protocols. Values shown represent the mean±s.e.m. value of four independent experiments. (D) Bar graph illustrating the levels of
CXC-chemokine secretion from PC3 cells 24h post-treatment with 1nM Doc or 10nM DEX, administered singly or in combination and calculated from
three independent experiments. (E and F)A si n( B and D), respectively, except that experiments were conducted in hBMECs. Statistically significant
differences in activity, transcript levels or secretion were determined using a two-tailed Student’s t-test analysis. *Po0.05; **Po0.01; ***Po0.001.
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Concentration-response curves, modelling to a two-site competi-
tion equation were generated, suggesting two different modes
of action of docetaxel activity in PC3 cells. A concentration-
dependent decrease in cell viability was observed following
treatment with docetaxel with a calculated IC50 value of 2.17nM.
However, concurrent administration of DEX (10nM) failed to
enhance the cytotoxicity of docetaxel (IC50 3.31nM) or indeed, alter
the distribution of viable cells across the two-distinct populations
(Figure 3A). Similarly, concurrent administration of DEX did
not influence the cytotoxicity of docetaxel in hBMECs (data not
shown).
Clinically, DEX is given to patients in the 24h before docetaxel.
As concurrent treatment of DEX (10nM) failed to alter the potency
of docetaxel, we conducted a further series of experiments
examining the effect of pre-treating PC3 cells with DEX before
docetaxel administration. The PC3 cells were treated with DEX
(10nM) for 48h, followed by treatment with docetaxel over a
concentration range of 0.01nM to 100mM for 72h. Control samples
were not pre-treated with DEX. Cell viability was assessed by
performing MTT assays. However, pre-treatment with DEX was
observed to decrease the cytotoxicity of docetaxel by a factor of
five-fold (IC50 5.94nM), as compared to control (1.2nM). There-
fore, scheduling has no apparent effect on the ability of DEX to
increase docetaxel cytotoxicity in CRPC cells (Figure 3C). Experi-
ments were also conducted using another taxane, paclitaxel.
Co-administration of DEX similarly failed to increase the potency
of paclitaxel in PC3 cells (Figure 3D).
Suppression of NF-jB activation or extracellular IL-8 levels
does not enhance docetaxel-induced cytotoxicity in PC3
cells
To determine whether a more potent and direct inhibition of NF-
kB activity may potentiate the cytotoxicity of docetaxel, PC3 cells
were treated with docetaxel in the absence and presence of the NF-
kB inhibitor, BAY11-7082, administered at a final concentration of
5mM. However, BAY11-7082 failed to potentiate the cytotoxicity of
docetaxel upon PC3 cells (Figure 4A). We also determined whether
the potentiation of IL-8 signalling in response to docetaxel may
assist in enabling PC3 cells to withstand taxane therapy.
Interleukin-8 signalling was initially inhibited using a neutralising
anti-IL-8 monoclonal antibody, administered at a concentration
of 4mgml
 1. However, no potentiation of docetaxel sensitivity
was observed following the inhibition of extracellular IL-8 levels in
the PC3 cell media (Figure 4B). In a further series of experiments,
we used the CXCR2 antagonist AZ10397767 at a concentration of
20nM to attenuate any potential signalling effect resulting from the
activity of additional, closely related CXC-chemokines to IL-8 (e.g.,
CXCL1). However, co-administration of AZ10397767 also had no
effect on the cytotoxicity of docetaxel (Figure 4C) or paclitaxel
(Figure 4D) in the PC3 cells. Therefore, direct (BAY11-7082) or
A
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Figure 3 Effect of dexamethasone (DEX) upon the cytotoxicity of taxanes to CaP cells. Graphs showing the effect of docetaxel, in the absence and
presence of 10nM DEX, upon the viability of (A) PC3 and (B) LNCaP cells. Data points shown on the graphs represent the mean±s.e.m. value calculated
from four and three experiments, respectively. (C) Graph showing the effect of docetaxel, following pre-treatment (48h) of PC3 cells with 10nM DEX. The
data points shown represent the mean±s.e.m. of three independent experiments. (D) Graph showing the effect of paclitaxel in the absence and presence
of 10nM DEX upon the viability of PC3 cells. The data points shown represent the mean±s.e.m. of three independent experiments. In all scenarios, DEX
failed to enhance the cytotoxicity of taxanes on CaP cells.
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two of its downstream signalling effectors (IL-8/CXCR2) does not
appear to sensitise PC3 cells to the effects of docetaxel.
DEX potentiates the antiangiogenic activity of docetaxel
Dexamethasone and docetaxel are independently associated with
the promotion of antiangiogenic effects in in vivo models of
cancer. Therefore, in the absence of DEX modulating the
cytotoxicity of docetaxel to CRPC cells, we investigated whether
the capacity of DEX to attenuate the docetaxel-induced expression
of proangiogenic factors may enhance the established antiangio-
genic activity of taxanes. Initially, we used a commercial AngioKit
assay (TCS), which reproduces the different phases of angio-
genesis. Docetaxel (1nM) and/or DEX (10nM) were added to the
AngioKit wells every 72h and the assay was conducted for 11 days
before staining with CD31 as described in Materials and Methods.
Administration of DEX alone had a minimal but not statistically
significant effect upon either mean vessel area or mean vessel
length (Figure 5B). Docetaxel, in contrast, had a marked effect on
vessel development resulting in an almost 90% reduction in mean
vessel area (Po0.05) and an over 70% reduction in mean vessel
length compared with untreated cells (Po0.05) (Figure 5B).
Interestingly, co-administration of DEX was observed to potentiate
the antiangiogenic activity of docetaxel. The mean vessel area was
reduced by a further 50% in cells treated with DEX and docetaxel
compared with the effect of docetaxel alone (Po0.01). Similarly,
mean vessel length was also reduced by 50% following co-
administration of DEX with docetaxel (Po0.05) (Figure 5C).
The antiangiogenic effect of DEX and docetaxel was studied
further, exploiting a chamber assay in the skin flap of SCID mice to
determine the effect of these agents upon the vascularisation of an
implanted fragment of a PC3 tumour. The parameters of vessel
diameter, branch points and segment length were measured from
images taken of the growing tumours at days 9, 11, 15 and 18 post-
implantation (drug treatments initiated on day 8). Images shown
compare the effect of DEX on tumour vasculature against the
potent antiangiogenic effect of co-administering DEX with
docetaxel over the 10-day period (Figure 6A). A comparison of
the effect of vehicle control, DEX, docetaxel and the combined
DEX/docetaxel treatment on the organisation of the tumour
vasculature at day 10 post-treatment is also shown (Figure 6B).
Images of the tumour vasculature were subjected to further
quantitative analysis. Treatment with DEX alone resulted in no
significant difference in vessel diameter (Figure 6C), the number of
branch points observed (Figure 6D) or the average segment length
of the blood vessel (Figure 6E) relative to control over the course of
the experiment. In contrast, administration of docetaxel resulted in
a marked reduction in the number of small diameter blood vessels
that could be observed throughout the tumour mass 7 (P¼0.018)
and 10 days (P¼0.011) post-treatment relative to control
(Figure 6C). This coincided with a decrease in the number of
vessel branch points detected (Figure 6D) and an increase in the
vessel segment length (Figure 6E) measured within the tumours on
each of these days.
The combination of DEX with docetaxel enhanced the
antiangiogenic response further, potentiating the increase in
the average vessel diameter and vessel segment length within the
tumour and reducing further the number of vessel branch points
detected, relative to the effect of docetaxel alone, 7 and 10 days
post-treatment. This was particularly evident in quantifying the
number of branch points where statistically significant differences
between the DEX/docetaxel and docetaxel treatments were
observed at days 7 (Po0.001) and 10 (Po0.05). With respect to
the other parameters under investigation, the trend towards an
increase in the vessel diameter and segment length in the DEX/
docetaxel-treated tumours relative to docetaxel alone approached
but did not attain statistical significance in a two-tailed t-test in
this experimental design (e.g., P¼0.06 for difference in segment
length and diameter at day 10). Furthermore, although again not
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Figure 4 Effect of inhibiting NF-kB, IL-8 or CXC-chemokine expression upon taxane cytotoxicity to PC3 cells. Graphs presenting the effect of co-
administering (A)5mM BAY-11-7082, (B)4mgml
 1 anti-IL-8 monoclonal Ab, or (C)2 0n M AZ10397767 upon the cytotoxicity of docetaxel in PC3 cells.
(D) Graph presenting the effect of administering increasing concentrations of paclitaxel in the absence and presence of 20nM AZ10397767 upon the
viability of PC3 cells. Data points shown represent the mean±s.e.m. of three or four independent experiments. In all scenarios presented in this figure,
pharmacological interventions inhibiting the NF-kB pathway or proangiogenic CXC-chemokine signalling failed to enhance the cytotoxicity of taxanes on
PC3 cells.
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DEX with docetaxel increases the rate of onset of the observed
antivascular effect in the tumours, supported by the detection of an
increased average vessel diameter and average segment length
within 3 days of treatment.
DISCUSSION
Docetaxel is at present the chemotherapy agent of choice in the
treatment of metastatic CRPC. To offset the risk of developing
docetaxel-induced hypersensitivity, patients treated with docetaxel
also received DEX pre-medication (Tannock et al, 2004). As DEX
administration alone has been reported to have clinical benefit in
CRPC patients (Venkitaraman et al, 2008), this has led to
speculation that DEX may contribute in part to the increased
survival benefit of patients receiving docetaxel. The objective of
our study was to characterise a mechanism that may explain a
synergy by which DEX may potentiate the clinical benefit of
docetaxel in patients with CRPC.
Experiments were conducted primarily on the representative
CRPC cell line PC3 (originally derived from a bony metastasis of
human prostate carcinoma) with key experiments repeated in a
transformed bone marrow endothelial cell line, as outgrowth of
secondary lesions within the bone is the predominant complica-
tion associated with CRPC. Consistent with its anti-inflammatory
action, we observed that DEX administration decreased the
constitutive NF-kB transcriptional activity in the PC3 cells.
Consequently, we were able to show a decreased transcription
and/or secretion of the CXC-chemokines IL-8 and CXCL1 and the
proangiogenic growth factor, VEGF. This response was also
observed in hBMECs, where DEX treatment resulted in the
suppression of IL-8 and CXCL1 gene transcription and/or
secretion.
Constitutive activity of NF-kB has been reported in CaP cell
lines and/or biopsy tissue and is associated with regulating the
expression of genes that induce cell proliferation and/or underpin
cell survival (Huang et al, 2001; Fradet et al, 2004; Ross et al, 2004;
Shukla et al, 2004; Sweeney et al, 2004; Domingo-Domenech et al,
2005). However, despite suppressing the constitutive activity of the
NF-kB transcription factor, DEX administration failed to reduce
the proliferation or the viability of PC3 tumour cells or hBMECs. In
addition, we observed that co- or pre-administration of DEX failed
to potentiate the cytotoxicity of docetaxel in PC3 cells. Interest-
ingly, our findings support several previous observations that
report the absence of a cytotoxic or antiproliferative effect of DEX
in CaP cells. For example, DEX has been reported to antagonise
rather than enhance the potency of conventional cytotoxic
chemotherapy agents, including doxorubicin, cisplatin or etopo-
side, in PC3 cells (Carollo et al, 1998). Indeed, DEX has been
shown to induce resistance to several cytotoxic agents, including
the taxane, paclitaxel, in cells isolated from surgical resections of
prostate tumours (Zhang et al, 2006) and to a range of cytotoxics
in xenograft models of CaP (Zhang et al, 2007). Studies in
macrophages, endothelial, airway smooth muscle and cancer cells
have shown that DEX-induced glucocorticoid receptor signalling
increases the expression of MAPK phosphatase-1, resulting in
decreased MAPK signalling in these cells and contributing to the
anti-inflammatory effect (Wu et al, 2005; Abraham et al, 2006;
Furst et al, 2007; Issa et al, 2007). Interestingly, overexpression of
MAPK phosphatase-1 has been shown to attenuate taxane-
induced, proapoptotic JNK signalling in breast cancer cells (Wu
et al, 2005). Therefore, this suggests a possible mechanism to
explain why DEX fails to enhance the sensitivity of CaP or
endothelial cells to docetaxel-induced cytotoxicity.
Taxane administration has previously been reported to induce
the expression of the proangiogenic CXC chemokine IL-8 in a
range of cancer cell lines (Collins et al, 2000; Uslu et al, 2005). We
too have observed this effect in PC3 cells and hBMECs. Docetaxel
administration potentiated the transcriptional activity of AP-1 and
NF-kB in PC3 cells and hBMECs, resulting in increased synthesis
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Figure 5 Enhancement of the antiangiogenic effect of docetaxel by
combination with dexamethasone (DEX) in endothelial tube formation
assays. (A) Representative field images of endothelial tube formation
following administration of a vehicle control (top left quadrant), 10nM DEX
(top right quadrant), 1nM docetaxel (Doc) (lower right quadrant) and 1nM
docetaxel co-administered with 10nM DEX (lower right quadrant). All
images shown are at a magnification of  10. (B) Quantitation of mean
vessel area (mm
3) (left panel) and mean vessel length (mM)( r i g h tp a n e l )a s
determined from analysis of 10 representative fields in vehicle control-, 10nM
DEX- or 1nM Doc-treated endothelial cells. Columns represent the
mean±s.e.m. value. (C) Comparison of the mean vessel area (mm
3)( l e f t
panel) and mean vessel length (mM) (right panel) as determined by image
analysis of 10 representative fields in wells receiving 1nM Doc-treated vs 1n M
Doc plus 10nM DEX. Columns represent the mean±s.e.m. value. Statistically
significant differences in vessel area and length in (B)a n d( C)w e r e
determined using a two-tailed Student’s t-test analysis. *Po0.05; **Po0.01.
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sand secretion of IL-8 and a related CXC-chemokine CXCL1.
However, co-administration of DEX was observed to attenuate the
docetaxel-induced AP-1 and NF-kB transcriptional activity and
abrogated docetaxel-induced CXC-chemokine gene transcription
and secretion in PC3 cells and endothelial cells. We have recently
reported that the induction of IL-8 signalling in hypoxic and
normoxic CaP cell lines activates cell survival signalling and
confers a survival advantage to these cells in response to DNA-
damage agents (Maxwell et al, 2007; Wilson et al, 2008b),
antiandrogens (Seaton et al, 2008) and biological inducers of
apoptosis such as TNF-receptor apoptosis-inducing ligand (Wilson
et al, 2008a). Direct inhibition of NF-kB using BAY11-7082 or
direct antagonism of IL-8 signalling, targeting the ligand with a
neutralising antibody or through a CXCR2-receptor antagonist,
failed to potentiate the cytotoxicity of docetaxel in these cells. It
has been previously reported that overexpression of IL-8 in
ovarian cancer cells had no appreciable effect on paclitaxel
resistance in vitro (Duan et al, 2002). However, recent in vivo
studies using liposome-encapsulated siRNA oligonucleotides to
target IL-8 expression has shown that targeting this chemokine
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Figure 6 Enhancement of the antiangiogenic effect of docetaxel by combination with dexamethasone (DEX) in a dorsal skin flap assay. PC3 tumour
fragments were implanted in a subcutaneous ‘window chamber’ apparatus on the backs of SCID mice. The development of intratumoural blood vessels was
imaged over a 10-day period following treatment with DEX or docetaxel (Doc). The vasculature was visualised using a multiphoton confocal microscope
following a tail vein injection of 50ml of 150kDa FITC-labeled dextran (50mgml
 1). (A) Representative images showing the response of blood vessel in
PC3 tumours receiving 10nM DEX (top panel) or combined treatment with 10nM DEX plus 0.5nM Doc. Images clearly depict a reduction in blood vessels in
tumours receiving Doc. (B) Representative images showing the comparison of the vasculature within PC3 tumours 10-day post-initiation of treatment
administration. Images shown are for vehicle control (top left quadrant), 10nM DEX (top right quadrant), 0.5nM Doc (lower left quadrant) and the
combined treatment of 10nM DEX plus 0.5nM Doc (lower right quadrant). The loss of small vessels is again evident in the Doc-treated tumours with further
selection for large diameter vessels in those tumours receiving the combined DEX/Doc treatment. (C) Quantitative analysis of vessel diameter in vehicle
control-, 10nM DEX-, 0.5nM Doc and 10nM DEX/0.5nM Doc-treated PC3 tumours at four different times post-initiation of treatment. Bars shown represent
the mean±s.e.m. value calculated from the analysis of 10 independent fields in each of five mice. (D)A si n( C) except that bars represent the mean±s.e.m.
number of vessel branch points determined in the tumours. (E)A si n( C) except that bars represent the mean±s.e.m. value calculated for vessel segment
length determined in the tumours. Statistically significant differences in vessel diameter, number of branch points or vessel segment length were determined
using a one-way ANOVA. *Po0.05; **Po0.01; ***Po0.001.
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sreduces microvessel density and significantly enhances the
antiproliferative effect of docetaxel on HeyA8 and SKOV3ip1
ovarian tumour growth (Merritt et al, 2008).
Dexamethasone has been shown to suppress proangiogenic gene
transcription and secretion in a range of CRPC cells in vitro,
whereas a subcutaneous administration of DEX inhibits tumour
growth and angiogenesis in an in vivo DU145 xenograft model of
CRPC (Yano et al, 2006). The impact of co-administering DEX on
the antiangiogenic activity of docetaxel was initially studied using
an in vitro assay that measures the capacity of endothelial cells to
promote vessel development in a co-culture system. Dexametha-
sone had a minimal but not statistically significant effect in
reducing the development of CD31þ vessels. However, addition of
DEX did potentiate the pronounced antiangiogenic activity of
docetaxel, reducing both the observed mean vessel length and
mean vessel area. This result was further confirmed through real-
time imaging of the vasculature in an implanted PC3 tumour in an
SCID mouse, showing a significant loss of intratumoural vascular
development in tumours that were concurrently treated with DEX
and docetaxel. A pronounced decrease in vessel branching and a
reduction in the number of small developing vessels within the
tumour was clearly visible within the tumour, consistent with the
reduced capacity of the tumour to stimulate de novo vessel
development. Therefore, the ability of DEX to suppress IL-8,
CXCL1 and VEGF would appear to underpin an enhanced
suppression of the tumour vasculature in the PC3 model of CRPC
and potentiate the antiangiogenic effect of docetaxel. Conse-
quently, using either DEX to inhibit IL-8 gene expression in CRPC
cells or the IL-8 gene-silencing strategy in ovarian cancer cells
(Merritt et al, 2008) indicates that IL-8 signalling does not
modulate the mechanistic basis of taxane-induced cell death in
tumour cells. Instead, these studies both suggest that suppressing
the level of IL-8 signalling capacity within the microenvironment
of the tumour clearly enhances the therapeutic benefit of taxanes,
mediated through a pronounced suppression of angiogenesis
within the tumour. Although these studies have not delineated
the mechanism underpinning the reduced vascularisation ob-
served in the DEX/docetaxel-treated tumours, the apparent
absence of an effect in regulating endothelial cell survival
suggests that the decrease in CXC-chemokine signalling potential
within the tumour may attenuate the capacity of endothelial cells
to migrate and/or promote tube formation. Understanding the
mechanism of action will be the subject of future experiments in
our laboratory.
In conclusion, we have shown that DEX attenuates docetaxel-
induced AP-1 and NF-kB activation, reducing the synthesis of
proangiogenic factors in both CaP and endothelial cells, with an
ultimate effect of reducing de novo vessel development in a
prostate tumour. Our data indicate that DEX potentiates the
antiangiogenic as opposed to the cytotoxic activity of docetaxel on
tumour cells. Angiogenesis is critical in accelerating primary
tumour growth and in establishing colonisation at secondary sites
and therefore, may explain why a combination of these two agents
extends the median survival of patients with advanced CaP.
Consequently, many of the novel antiangiogenic agents under-
going clinical trials may find significant utility and purpose in
treating CRPC, especially in combination with existing agents such
as docetaxel.
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